Live
Home·Deals·biotechnology·BioNTech SE acquires CureVac
BioNTech SE acquires CureVac (2026)
SEO URLwww.firestrike.ai/deals/curevac-biontech-se-acquisition-2026-6
acquisitionAnnounced · Jan 9, 2026biotechnologySource · CredibleArticle · Factual
CureVac
BioNTech SE
CureVac · BioNTech SE

BioNTech SE acquires CureVac

David Najork
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
ShareXLinkedInEmail
Deal value
$1.25B
Target
CureVac
CureVac
Tuebingen, Baden-Wuerttemberg
Acquirer
BioNTech SE
BioNTech SE
Full Acquisition
Status
Announced

BioNTech SE agreed to acquire CureVac. Reported deal value: $1.25B. Status: Announced. Sector: biotechnology. Target headquarters context: Tuebingen, Baden-Wuerttemberg, Germany.

This page summarizes publicly available information about the transaction as of 2026-01-09. Figures and status may change as filings and press coverage update.

MarketMinute January 09, 20 26 at 10:57 AM EST In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE has officially completed its acquisition of longtime rival CureVac N.V.

Deal timeline

Announced
Jan 9, 2026 · markets.financialcontent.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context

This transaction is classified in biotechnology with a reported deal value of $1.25B. Figures and status may change as sources update.

Sources: markets.financialcontent.com · Primary article · FireStrike proprietary index